OTCMKTS:ZLDPF Zealand Pharma A/S Q1 2025 Earnings Report $44.75 -0.26 (-0.58%) As of 09:36 AM Eastern ProfileEarnings HistoryForecast Zealand Pharma A/S EPS ResultsActual EPS-$0.67Consensus EPS -$0.77Beat/MissBeat by +$0.10One Year Ago EPSN/AZealand Pharma A/S Revenue ResultsActual Revenue$1.14 millionExpected Revenue$248.61 millionBeat/MissMissed by -$247.47 millionYoY Revenue GrowthN/AZealand Pharma A/S Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsZealand Pharma A/S' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Zealand Pharma A/S Earnings HeadlinesZealand Pharma - Transactions related to share buy-back program (week 24, 2026)June 15 at 11:31 AM | markets.businessinsider.comDrugmakers race to find a place in the next wave of obesity drugsJune 13, 2026 | cnbc.comHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's not personal failure. That's what happens when the environment your retirement depends on changes without you ever being told. The cost shows up later, as the retirement you didn't get to live. Garrett Goggin, CFA, CMT, Lead Analyst at Golden Portfolio, breaks down exactly how much this drift is costing you - and what you can do about it.June 18 at 1:00 AM | Golden Portfolio (Ad)Roche and Zealand Advance Combo Obesity Drug Trial, Signaling New Momentum for ZLDPFJune 12, 2026 | tipranks.comZealand Pharma - Transactions related to share buy-back program (week 23, 2026)June 8, 2026 | markets.businessinsider.comZealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side EffectsJune 8, 2026 | wsj.comSee More Zealand Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email. Email Address About Zealand Pharma A/SZealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited. Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access. Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.View Zealand Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Credo Technologies Accelerates AI—Its Stock Price Will FollowCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeJabil Just Gave Investors a Stronger Reason to Buy the DipCan Trupanion Turn Pet Insurance Loyalty Into Real Earnings?Okta’s AI Moment May Be Bigger Than Investors RealizeDave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanMicrosoft’s Xbox Problem Is Bigger Than a Console War Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
